Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial-Reference-Cited by-同舟云学术

Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

Published:2004-06 Issue:3 Volume:85 Page:247-254
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Thürlimann Beat,Hess Dagmar,Köberle Dieter,Senn Isabella,Ballabeni Pierluigi,Pagani Olivia,Perey Lucien,Aebi Stefan,Rochlitz Christoph,Goldhirsch Aron

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.springerlink.com/index/pdf/10.1023/B:BREA.0000025420.78346.f9

Reference9 articles.

1. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83: 1142–1152, 1998

2. Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women-results of the TARGET (Tamoxifen or ArimidexTM Randomised Group Efficacy and Tolerability) study. J Clin Oncol 18: 3748–3757, 2000

3. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicentre randomized trial. J Clin Oncol 18: 3758–3776, 2000

4. Bonneterre J, Buzdar A, Nabholtz JM, R obertson JF, Thürlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M, Arimidex Writing Committee, Investigators Committee Members: Anastrozole (Arimidex) is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast cancer: Results of two randomized trials designed for combined analysis. Cancer 92: 2247–2258, 2001

5. Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF, Thurlimann B: Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 39: 1684–1689, 2003

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer;npj Breast Cancer;2024-08-22

2. Targeting nuclear hormone receptors for the prevention of breast cancer;Frontiers in Medicine;2023-07-31

3. Role of 18F-FDG PET/CT in evaluation of recently diagnosed breast cancer patients;Egyptian Journal of Radiology and Nuclear Medicine;2022-08-12

4. In silico docking and ADME study of deketene curcumin derivatives (DKC) as an aromatase inhibitor or antagonist to the estrogen-alpha positive receptor (Erα+): potent application of breast cancer;Structural Chemistry;2022-01-28

5. Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis;Breast Care;2022